TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 10579275
Drug: Standard enteral
Normalized name: Standard enteral formula
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard enteral nutrition (gradually increased from 15 mL/hr up to estimated energy and nitrogen requirements)
Study: 1744924
Drug: Intravenous administration
Normalized name: intravenous administration set
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous administration of leucovorin
Study: 1744924
Drug: Oral administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral administration of leucovorin
Study: 6126069
Drug: Communication-oriented group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Communication-oriented group therapy
Study: 21705294
Drug: Pioglitazone 30
Normalized name: pioglitazone 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pioglitazone 30 mg daily for 12 weeks
Study: 20074897
Drug: Water 0.1
Normalized name: nitroglycerin in 5 % dextrose in water 0.1 mg/mL INTRAVEN INFUSION BOTTLE (ML)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Water 0.1 ml/kg (G2)
Study: 17409263
Drug: Glucose supplements
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glucose supplements (G) - 6.13 +/‐ 0.09% glucose
Study: 14986145
Drug: Contrast enhancement
Normalized name: Contrased
Approvals — FDA: no, EMA: no, PMDA: no
Description: Contrast enhancement administered in 11 cases
Study: 11566640
Drug: Psyllium supplement
Approvals — FDA: no, EMA: no, PMDA: no
Description: Psyllium supplement (15 g psyllium/d)
Study: 7868693
Drug: Medical abortion
Normalized name: ABSORPTION BASE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medical abortion (mifepristone 600 mg followed by gemeprost 1 mg vaginal pessary)
Study: 29956790
Drug: Isomaltulose (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isomaltulose (20 g)
Study: 26754305
Drug: Levothyroxine soft
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levothyroxine soft capsules (600 μg)
Study: 26754305
Drug: Levothyroxine tablets
Normalized name: levothyroxine Oral Tablet
DrugBank: Levothyroxine (DB00451)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Levothyroxine tablets (200 μg)
Study: 26754305
Drug: Low, medium,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low, medium, and high strengths of levothyroxine soft capsules
Study: 20631675
Drug: Erythropoiesis-stimulating agents
Approvals — FDA: no, EMA: no, PMDA: no
Description: Erythropoiesis-stimulating agents (ESA) treatment
Study: 18614402
Drug: 1.5 mg
Normalized name: boron 1.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.5 mg slow release indapamide, with the option of 2‐4 mg perindopril
Study: 8966389
Drug: ACTH stimulation
Normalized name: ACTH
DrugBank: Corticotropin (DB01285)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: ACTH stimulation test (0.25 mg iv bolus)
Study: 8966389
Drug: 1 mg
Normalized name: biotin 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg oral midnight DEX inhibition test
Study: 8966389
Drug: 100-g 2-h
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100-g 2-h oral glucose tolerance test (OGTT)
Study: 8966389
Drug: Comparison of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Comparison of basal luteinizing hormone (LH) and follicle-stimulating hormone (FSH) ratio
Study: 6125820
Drug: Daily bag-changing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily bag-changing regimen
Study: 6125820
Drug: Weekly bag-changing
Normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Weekly bag-changing regimen
Study: 31487279
Drug: Antibacterial treatment
Normalized name: Dermoplast Antibacterial
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antibacterial treatment
Study: 31469393
Drug: Sequential choice
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sequential choice (colonoscopy and then FIT)
Study: 26273677
Drug: Insulin and
Normalized name: Isophane insulin and porcine regular insulin only product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Insulin and rosiglitazone 4 mg/day (n = 30)
Study: 26273677
Drug: Insulin alone
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Insulin alone (n = 31)
Study: 19502256
Drug: Rapamycin-eluting stents
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rapamycin-eluting stents with adjunct oral valsartan
Study: 15852444
Drug: Memantine 10
Normalized name: Memantine 10mg Oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Memantine 10 mg b.i.d.
Study: 11961446
Drug: Short-term intravenous
Normalized name: hydrogen peroxide
DrugBank: Hydrogen peroxide (DB11091)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Short-term intravenous antibiotics (7 days for joint infection, 10 days for bone infection)
Study: 11961446
Drug: Long-term intravenous
Normalized name: benzethonium
DrugBank: Benzethonium (DB11125)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Long-term intravenous antibiotics (14 days for joint infection, 21 days for bone infection)
Study: 7661494
Drug: Cefixime (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefixime (400 mg every 24 hours for 5 days)
Study: 7661494
Drug: Pivamdinocillin (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pivamdinocillin (400 mg every 6 hours for 5 days)
Study: 30544335
Drug: IL13‐Pseudomonas exotoxin
Approvals — FDA: no, EMA: no, PMDA: no
Description: IL13‐Pseudomonas exotoxin (IL13‐PE38QQR) administered via intratumoral convection enhanced delivery (CED) at 0.125 µg/mL
Study: 30544335
Drug: IL13‐Pseudomonas exotoxin
Approvals — FDA: no, EMA: no, PMDA: no
Description: IL13‐Pseudomonas exotoxin (IL13‐PE38QQR) administered via intratumoral convection enhanced delivery (CED) at 0.25 µg/mL
Study: 30544335
Drug: IL13‐Pseudomonas exotoxin
Approvals — FDA: no, EMA: no, PMDA: no
Description: IL13‐Pseudomonas exotoxin (IL13‐PE38QQR) administered via CED
Study: 25022834
Drug: Exceeding Recommended
Normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Exceeding Recommended Daily Upper Level for sodium intake at 18 months
Study: 27718262
Drug: Tulobuterol patch
Normalized name: tulobuterol
DrugBank: Tulobuterol (DB12248)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tulobuterol patch (TP)
Study: 20440023
Drug: Simulated Developmental
Normalized name: bisacodyl
DrugBank: Bisacodyl (DB09020)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Simulated Developmental Horse‐Riding Program (SDHRP) in addition to regular occupational therapy
Study: 20440023
Drug: Regular occupational
Approvals — FDA: no, EMA: no, PMDA: no
Description: Regular occupational therapy only
Study: 18702964
Drug: Aggressive LDL-C
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aggressive LDL-C lowering with lovastatin 40 to 80 mg/day (target LDL-C of 60 to 85 mg/dl)
Study: 18702964
Drug: Moderate LDL-C
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moderate LDL-C lowering with lovastatin 2.5 to 5 mg/day (target LDL-C of 130 to 140 mg/dl)
Study: 18574557
Drug: Motesanib diphosphate
Normalized name: trisodium diphosphate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Motesanib diphosphate 50 mg once daily from day 1 through 15 with ketoconazole 400 mg on day 8 (n=7)
Study: 18574557
Drug: Motesanib diphosphate
Normalized name: trisodium diphosphate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Motesanib diphosphate 125 mg once daily after day 16 (n=13)
Study: 9309995
Drug: Oral nutritional
Normalized name: Ocean Blue Nutritionals Omega-3 1450 Oral Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral nutritional supplementation (10 kcal/kg/d)
Study: 24700403
Drug: Clevidipine (0.2-8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clevidipine (0.2-8 μg·kg(‐1)·min(‐1))
Study: 24700403
Drug: Nitroglycerin (NTG)
DrugBank: Nitroglycerin (DB00727)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nitroglycerin (NTG) (0.4 μg·kg(‐1)·min(‐1) to a clinician‐determined maximum dose)
Study: 19230981
Drug: Aripiprazole (15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aripiprazole (15 mg/day, 20 mg/day, or 30 mg/day)
Study: 15584487
Drug: IFN-beta treatment
Normalized name: PEG IFN-beta-1a
DrugBank: Peginterferon beta-1a (DB09122)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: IFN-beta treatment
Study: 11425410
Drug: Reteplase alone
Normalized name: reteplase
DrugBank: Reteplase (DB00015)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Reteplase alone (standard-dose)
Study: 11425410
Drug: Reteplase plus
Normalized name: reteplase
DrugBank: Reteplase (DB00015)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Reteplase plus abciximab (half-dose reteplase and full-dose abciximab)
Study: 8037103
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg torsemide
Study: 8111802
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg torsemide
Study: 8111802
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg torsemide
Study: 27185372
Drug: 500 mg
Normalized name: bran 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 mg fulvestrant
Study: 18356332
Drug: Macadamia nut-rich
Normalized name: Macadamia nut
DrugBank: Macadamia nut (DB10655)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Macadamia nut-rich diet (42.5 g, 1.5 ounces, 33% total fat; 7% SFA, 18% MUFA, 5% PUFA)
Study: 12519049
Drug: Tibolone added
Normalized name: TIBOLONE
DrugBank: Tibolone (DB09070)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tibolone added to monthly triptoreline (3.75 mg every 28 days IM) treatment for six months.
Study: 12519049
Drug: Monthly triptoreline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Monthly triptoreline (3.75 mg every 28 days IM) treatment for six months.
Study: 12519049
Drug: Tibolone added
Normalized name: TIBOLONE
DrugBank: Tibolone (DB09070)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tibolone added to triptoreline treatment.
Study: 12519049
Drug: Triptoreline treatment.
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triptoreline treatment.
Study: 7497668
Drug: Enoxaparin 30
Normalized name: ENOXAPARIN 30MG/0.3ML INJ
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enoxaparin 30 mg subcutaneous every 12 hours
Study: 7497668
Drug: Unfractionated heparin
Normalized name: Unfractionated heparin
DrugBank: Heparin (DB01109)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Unfractionated heparin 5000 units subcutaneous every 8 hours
Study: 19803002
Drug: Ceftazidime 500
Normalized name: ceftazidime 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ceftazidime 500 mg
Study: 19803002
Drug: Ceftazidime 500
Normalized name: ceftazidime 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ceftazidime 500 mg or 1 g
Study: 28822576
Drug: Intravenous pembrolizumab
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous pembrolizumab every 2 weeks (n=279)
Study: 28822576
Drug: Intravenous pembrolizumab
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous pembrolizumab every 3 weeks (n=277)
Study: 28822576
Drug: Intravenous ipilimumab
Normalized name: Ipilimumab
DrugBank: Ipilimumab (DB06186)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Intravenous ipilimumab every 3 weeks (n=278)
Study: 19805702
Drug: Cocaine vaccine
Normalized name: Cocaine
DrugBank: Cocaine (DB00907)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cocaine vaccine (succinylnorcocaine linked to recombinant cholera toxin B-subunit protein)
Study: 11177086
Drug: Intramuscular ceftriaxone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular ceftriaxone followed by 10 days of oral trimethoprim-sulfamethoxazole (IM + PO group)
Study: 11177086
Drug: Oral trimethoprim-sulfamethoxazole
Normalized name: sulfamethoxazole / trimethoprim
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral trimethoprim-sulfamethoxazole alone (PO group)
Study: 9353802
Drug: 10-mg controlled
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10-mg controlled release oxybutynin tablet
Study: 9353802
Drug: 5-mg conventional
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5-mg conventional oxybutynin tablet
Study: 8216445
Drug: Single oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single oral dose of mosapride citrate (5 mg, 10 mg, 20 mg, 40 mg)
Study: 8216445
Drug: Multiple oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multiple oral dose of mosapride citrate (20 mg t.i.d. for one day, 10 mg t.i.d. for 8 days)
Study: 8216445
Drug: Single oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single oral dose of mosapride citrate (10 mg) with food effect
Study: 2957416
Drug: Ipratropium bromide
Normalized name: Ipratropium Bromide
DrugBank: Ipratropium (DB00332)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ipratropium bromide nasal spray (20 micrograms per spray, two sprays in each nasal cavity, four times daily for 3 weeks)
Study: 7751529
Drug: Ipratropium bromide
Normalized name: Ipratropium Bromide
DrugBank: Ipratropium (DB00332)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ipratropium bromide nasal spray
Study: 31313942
Drug: Dacomitinib (45
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dacomitinib (45 mg once-daily, with dose reductions to 30 mg and 15 mg QD)
Study: 21844547
Drug: Oseltamivir, 75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oseltamivir, 75 mg twice daily
Study: 21844547
Drug: Maxingshigan-yinqiaosan decoction,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Maxingshigan-yinqiaosan decoction, 200 mL 4 times daily
Study: 18998193
Drug: Aspirator retractor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirator retractor used during socket preparation and cementation
Study: 16430545
Drug: 6 mg
Normalized name: boron 6 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6 mg of isobaric bupivacaine
Study: 16430545
Drug: 7 mg
Normalized name: pectin 7 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 7 mg of isobaric bupivacaine
Study: 16430545
Drug: 8 mg
Normalized name: alloin 8 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 8 mg of isobaric bupivacaine
Study: 16430545
Drug: 9 mg
Normalized name: fiber 469 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 9 mg of isobaric bupivacaine
Study: 16430545
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg of isobaric bupivacaine
Study: 16430545
Drug: 12 mg
Normalized name: pectin 12 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 12 mg of isobaric bupivacaine
Study: 9282235
Drug: Nebulized L-NAME
Normalized name: L-NAME
DrugBank: N-omega-nitro-L-arginine methyl ester (DB12750)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nebulized L-NAME (15 mg in saline)
Study: 8356861
Drug: Omeprazole (80
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omeprazole (80 mg orally)
Study: 8356861
Drug: Ranitidine (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ranitidine (300 mg orally)
Study: 8356861
Drug: Control (no
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (no antacid therapy)
Study: 3041822
Drug: Uniphyl tablets
Normalized name: Uniphyl Tablets 400 MG Extended Release Oral Tablet
DrugBank: Theophylline (DB00277)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Uniphyl tablets administered once daily at bedtime
Study: 3041822
Drug: Theo-Dur tablets
DrugBank: Theophylline (DB00277)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Theo-Dur tablets administered twice daily
Study: 26791440
Drug: Schema therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Schema therapy (ST) training with peer supervision and limited expert supervision after a 4-day training.
Study: 19563648
Drug: N-acetylcysteine (NAC)
DrugBank: Acetylcysteine (DB06151)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: N-acetylcysteine (NAC) 600 mg BID, starting 24 h before the procedure
Study: 16226012
Drug: DHA supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: DHA supplementation (algal oil providing 50 mg of DHA per kilogram per day for 6 months)
Study: 8420684
Drug: Chemotherapy regimens
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy regimens (five different regimens)
Study: 3510820
Drug: Inhaled metaproterenol
Normalized name: metaproterenol Inhalation Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled metaproterenol (1.30 mg six times a day)
Study: 3510820
Drug: Sustained-release theophylline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sustained-release theophylline (plasma levels of 10-15 micrograms/ml)
Study: 3510820
Drug: Combined drug
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined drug therapy (metaproterenol + theophylline)
Study: 28894067
Drug: Empowerment Education
Normalized name: reductic acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Empowerment Education Program (EEP) for kidney transplant patients, conducted weekly for six weeks
Study: 15764050
Drug: Ultrasound rated
Normalized name: tacrolimus
DrugBank: Tacrolimus (DB00864)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ultrasound rated at 1 W/cm(2) with compressive therapy (Group A)
Study: 15764050
Drug: Ultrasound rated
Normalized name: tacrolimus
DrugBank: Tacrolimus (DB00864)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ultrasound rated at 0.5 W/cm(2) with compressive therapy (Group B)
Study: 15764050
Drug: Topical pharmacological
Normalized name: COPD pharmacologic substance
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical pharmacological treatment (Group C)
Study: 12198045
Drug: Magnesium sulfate,
Normalized name: MAGNESIUM SULFATE,ANHYDROUS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Magnesium sulfate, 2.48 mmol, injected 20 s before propofol administration
Study: 10536243
Drug: Witepsol H15
Normalized name: Witepsol H15 for Compounding
Approvals — FDA: no, EMA: no, PMDA: no
Description: Witepsol H15 (fast drug-releasing suppository)
Study: 10536243
Drug: Witepsol W35
Approvals — FDA: no, EMA: no, PMDA: no
Description: Witepsol W35 (slow drug-releasing suppository)
Study: 7763215
Drug: Isolutrol 0.15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isolutrol 0.15 g/100 mL (Ketsugo)
Study: 2145499
Drug: 5% benzoyl
Normalized name: BENZOYL PEROXIDE 2.5 g in 100 mL TOPICAL SOAP [Benzoyl Acne Wash -2.5% Benzoyl Peroxide]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5% benzoyl peroxide lotion
Study: 9106905
Drug: ondansetron (0.15
Approvals — FDA: no, EMA: no, PMDA: no
Description: ondansetron (0.15 mg/kg)
Study: 27565521
Drug: Pretransplantation Cancer
Normalized name: Cancer/testis antigen 1
DrugBank: Cancer/testis antigen 1 (DB19291)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pretransplantation Cancer and Treatment Distress (CTXD)
Study: 24474520
Drug: Auscultation technique
Normalized name: zinc pyrithione
DrugBank: Pyrithione (DB06815)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Auscultation technique using a standard stethoscope over the catheter insertion site after injecting 2 mL of NaCl 0.9% solution.
Study: 24474520
Drug: Subcutaneous injections
Normalized name: immune globulin subcutaneous (human) - klhw Injection [Xembify]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous injections (control group) in the opposite arm.
Study: 23346249
Drug: Continued treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continued treatment for another 7 days
Study: 23346249
Drug: No treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: No treatment for the next 7 days
Study: 20922911
Drug: Levofloxacin (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levofloxacin (500 mg/daily)
Study: 9442783
Drug: Topical dorzolamide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical dorzolamide (3 times daily)
Study: 9442783
Drug: Oral acetazolamide
Normalized name: Acetazolamide
DrugBank: Acetazolamide (DB00819)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral acetazolamide 250 mg (single administration)
Study: 7734461
Drug: Usual care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Usual care plus frequent urine testing and acupuncture treatments
Study: 25245776
Drug: Scrambler therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Scrambler therapy for up to ten daily 30‐min sessions
Study: 19950325
Drug: High-intensity progressive
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-intensity progressive resistance training (PRT) for 24 weeks, twice weekly
Study: 15478851
Drug: Proton pump
Normalized name: Proton pump inhibitor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Proton pump inhibitor treatment for 4 weeks
Study: 9407268
Drug: Subjects' report
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects' report of exposure treatment undertaken at home
Study: 7624106
Drug: 99Tcm-sestamibi (MIBI)
Normalized name: 99mTc sestamibi
DrugBank: Technetium Tc-99m sestamibi (DB09161)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 99Tcm-sestamibi (MIBI) injection for SPET imaging
Study: 31175001
Drug: Quizartinib (60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quizartinib (60 mg orally once daily, with a 30 mg lead-in)
Study: 31175001
Drug: Chemotherapy (investigator's
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy (investigator's choice including low-dose cytarabine, mitoxantrone, etoposide, and others)
Study: 26692084
Drug: Magnesium sulfate
Normalized name: Magnesium Sulfate
DrugBank: Magnesium (DB14513)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Magnesium sulfate (65 mg elemental magnesium) twice per day
Study: 26692084
Drug: Placebo twice
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo twice per day
Study: 27429174
Drug: Pain-contingent treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pain-contingent treatment as usual (TAU)
Study: 17342074
Drug: High-energy yogurt
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-energy yogurt preload beverage (YP: 500 ml, 1988 kJ for men; 375 ml, 1507 kJ for women)
Study: 15494230
Drug: Salivary amylase
Normalized name: Salivary amylase
Approvals — FDA: no, EMA: no, PMDA: no
Description: Salivary amylase activity monitor using a testing-strip and optical analyzer measuring salivary amylase activity with a range of 0-200 kU/l within 150 s.
Study: 11341354
Drug: Levamisole (LMS)
Normalized name: Levamisole
DrugBank: Levamisole (DB00848)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Levamisole (LMS) at four different dose levels over 3 days
Study: 6343149
Drug: Oral etretinate,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral etretinate, 1 mg/kg b.w. for 8 weeks
Study: 28605730
Drug: Gemcitabine (1,200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gemcitabine (1,200 mg/m2) and Vinorelbine (25 mg/m2) intravenously on days 1 and 8 every 3 weeks
Study: 22996370
Drug: Autologous dendritic
Normalized name: COVID19 s-vax loaded autologous dendritic cell vaccine
DrugBank: COVID19 s-vax loaded autologous dendritic cell vaccine (DB15814)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Autologous dendritic cells (DC) loaded with antigens from tumor cells, injected subcutaneously in 500 µg of granulocyte‐macrophage colony stimulating factor, weekly for 3 weeks and then monthly for 5 months.
Study: 22996370
Drug: Irradiated autologous
Normalized name: Autologous cultured fibroblasts
DrugBank: Azficel-T (DB11051)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Irradiated autologous proliferating tumor cells, injected subcutaneously in 500 µg of granulocyte‐macrophage colony stimulating factor, weekly for 3 weeks and then monthly for 5 months.